Acumen PharmaceuticalsABOS -2.59%34 EV-to-EBITDA is -0.85 as of Jul. 11, 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 392 Biotechnology companies, Acumen Pharmaceuticals ranks worse than 255101.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Acumen Pharmaceuticals's enterprise value is $92.72 Mil.
Acumen Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-108.82 Mil. Therefore, Acumen Pharmaceuticals's EV-to-EBITDA for today is -0.85.
The historical rank and industry rank for Acumen Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ABOS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -73.36 Med: -9.21 Max: 0.84
Current: -0.85
During the past 7 years, the highest EV-to-EBITDA of Acumen Pharmaceuticals was 0.84. The lowest was -73.36. And the median was -9.21.
ABOS's EV-to-EBITDA is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs ABOS: -0.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Acumen Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Acumen Pharmaceuticals's share price for today is $2.63.
Acumen Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.860.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acumen Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acumen Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Acumen Pharmaceuticals's EV-to-EBITDA falls into.
Acumen Pharmaceuticals's current Enterprise Value is $92.72 Mil.
Acumen Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-108.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acumen Pharmaceuticals (ABOS) has a EV-to-EBITDA of -0.85 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Acumen Pharmaceuticals. According to the industry distribution chart, Acumen Pharmaceuticals ranks #999999 out of 392 companies in the Biotechnology industry.
Is Acumen Pharmaceuticals' EV-to-EBITDA too high?
Acumen Pharmaceuticals' current EV-to-EBITDA is -0.85. Based on the distribution chart, Acumen Pharmaceuticals ranks #999999 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' EV-to-EBITDA compare to YDES and PYXS?
According to the Biotechnology industry distribution chart, Acumen Pharmaceuticals ranks #999999 out of 392 companies for EV-to-EBITDA. This places Acumen Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Acumen Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acumen Pharmaceuticals's current EV-to-EBITDA is -0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current EV-to-EBITDA of -0.85. The current EV-to-EBITDA is -0.85. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current EV-to-EBITDA is -0.85 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score
Get the complete analysis for ABOS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABOS has been successfully added to your 
